Assessing 18F-Fluorocholine (18F-FCH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas Assessing 18F-Fluorocholine (18F-FCH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

…) View Results Links Source: http://ift.tt/2areIdY ClinicalTrials.gov processed this data on July 28, 2016 Published on BioPortfolio… Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health

bioportfolio.com

Total Shares: 0

from Data Alerts http://ift.tt/2aD3gz2
via IFTTT

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

WordPress spam blocked by CleanTalk.